RxDoctor Payments Data

Gennady Geskin, MD

Cardiovascular Disease · Jefferson Hills, PANPI 1053319434

Payments from drug & device makers

What this record shows

This record is dominated by other: $159,824 of the $244,400 with a category attached, or 65.4%. 57 manufacturers reported payments, led by Angiodynamics, Inc. at 56.3% of the total. Reporting peaked in 2024 at $79,422 and has fallen 84.3% since, to $12,479 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$244,400in general payments, 2019–2025

Across 873 payments — averaging $279.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$138K
  • Philips North America LLC$33K
  • Skye Orthobiologics LLC$29K
  • Abbott$13K
  • Guerbet LLC$7K
  • Boston Scientific$4K
  • plus $21K from 51 others
$75,488in research payments, 2019–2025

Across 26 payments — averaging $2903.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veryan Medical Incorporated$75K

What the payments were for

  • Consulting fees$15,2506%
  • Speaking & faculty fees$30,40012%
  • Travel & lodging$8,3633%
  • Food & beverage$24,84410%
  • Education$5,7202%
  • Other$159,82465%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$244,400 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$291,138
Medicare patients
320
Services billed
2,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$326,865
XareltoRivaroxaban128$124,374
Repatha SureclickEvolocumab93$80,910
BrilintaTicagrelor64$57,173
EntrestoSacubitril/Valsartan57$53,602
Nebivolol Hcl83$4,333
ClopidogrelClopidogrel Bisulfate407$4,280
Rosuvastatin Calcium209$4,174
Atorvastatin Calcium153$2,088
Enoxaparin Sodium18$1,646
Niacin ErNiacin16$1,470
Metoprolol Succinate60$1,082
Bumetanide19$1,052
Carvedilol122$864
Amlodipine Besylate81$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$731$326,865310 claims
Johnson & JohnsonXarelto$1,718$124,374128 claims
AstraZenecaBrilinta$775$57,17364 claims
NovartisEntresto$469$53,60257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Jefferson Hills

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →